LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

LLY

986.64

-1.73%↓

JNJ

228.71

+0.86%↑

ABBV

209.5

-0.44%↓

UNH

389.84

-0.97%↓

AZN

183.98

+1.3%↑

Home・Aktien・Gilead Sciences Inc.

Gilead Sciences Inc.

Geschlossen

BrancheGesundheitswesen

129.61 0.07

Buy Sell

Übersicht

Veränderung der Aktienkurses

24h

Aktuell

Min

129.13

Max

130.97

Schlüsselkennzahlen
By Trading Economics
Einkommen	-162M 2B
Verkäufe	-965M 7B
KGV Branchendurchschnitt	18.191 51.415
EPS	2.03
Dividendenrendite	2.43
Gewinnspanne	29.037
Angestellte	17,000
EBITDA	18M 2.4B

Empfehlungen
By TipRanks
Empfehlungen	Starkes Kaufsignal
12-Monats-Prognose	+23.34% upside

Dividenden
By Dow Jones
Dividendenrendite Branchendurchschnitt	2.43% 2.34%
Nächstes Ergebnis	6. Aug. 2026
Nächste Dividendenausschüttung	29. Juni 2026
Nächstes Ex-Dividendendatum	15. Juni 2026

Marktstatistiken
By TradingEconomics
Marktkapitalisierung	1.1B 166B
Vorheriger Eröffnungskurs	129.54
Vorheriger Schlusskurs	129.61

Nachrichtenstimmung

By Acuity

28%

72%

48 / 345 Ranking in Healthcare

Technischer Score

By Trading Central

Vertrauen

Very Strong Bearish Evidence

97.33 / 103.17 Unterstützung & Widerstand

Gilead Sciences Inc. Chart

Vergangene Performances sind kein verlässlicher Indikator für zukünftige Ergebnisse.

Peer-Vergleich

Kursveränderung

Gilead Sciences Inc. Prognose

Kursziel

By TipRanks

23.34% Vorteil

12-Monats-Prognose

Durchschnitt 159.83 USD 23.34%

Hoch 180 USD

Tief 122 USD

Basierend auf 22 Wall-Street-Analysten, die in den letzten 3 Monaten 12-Monats-Kursziele für Gilead Sciences Inc. – Dist angeboten haben.

Rating-Konsens

By TipRanks

Starkes Kaufsignal

22 ratings

Buy

Halten

Sell

Basierend auf 22 Analysten, die in den letzten 3 Monaten Aktienbewertungen für Gilead Sciences Inc. – Dist abgegeben haben.

Technischer Score

By Trading Central

97.33 / 103.17Unterstützung & Widerstand

Recent bearish events outweigh bullish events.

All events are bearish.

There is one bullish event.

Stimmung

By Acuity

48 / 345 Ranking in Gesundheitswesen

Finanzen

Vertriebs- und Verwaltungskosten

Betriebsaufwand

Gewinn vor Steuern

Verkäufe

Umsatzkosten

Bruttogewinn aus dem Verkauf

Zinsaufwand für Schulden

EBITDA

Betriebsergebnis

Über Gilead Sciences Inc.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; Marengo Therapeutics; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company has a collaboration with Terray Therapeutics, Inc. to discover and develop small molecule therapies; and LEO Pharma to develop, manufacture, and commercialize the small molecule oral STAT6 program. The company was incorporated in 1987 and is headquartered in Foster City, California.